tiprankstipranks
Agronomics Limited (GB:ANIC)
LSE:ANIC
Want to see GB:ANIC full AI Analyst Report?

Agronomics (ANIC) AI Stock Analysis

123 Followers

Top Page

GB:ANIC

Agronomics

(LSE:ANIC)

Select Model
Select Model
Select Model
Neutral 44 (OpenAI - 5.2)
Rating:44Neutral
Price Target:
5.00 p
▼(-21.88% Downside)
Action:Reiterated
Date:01/04/26
The score is weighed down primarily by weak financial performance (recent losses and persistently negative cash flow), with technicals also bearish (price below key moving averages and negative MACD). Valuation is additionally constrained by a negative P/E driven by losses and no dividend data to offset risk; the main positive is the debt-free balance sheet, though equity has been eroding.
Positive Factors
Sector Focus — Cellular Agriculture
A dedicated focus on cellular agriculture and alternative proteins positions the company in a structural, long-duration growth theme. This specialization supports differentiated deal flow and expertise across cultivated meat, precision fermentation and enabling tech, increasing the chance of high-return exits over time.
Negative Factors
Persistent Negative Cash Flow
Consistent negative operating and free cash flow indicates the company is not self-funding and must rely on capital raises or portfolio realizations to cover expenses. This persistent cash burn increases dilution risk and pressures the ability to support portfolio companies through cycles.
Read all positive and negative factors
Positive Factors
Negative Factors
Sector Focus — Cellular Agriculture
A dedicated focus on cellular agriculture and alternative proteins positions the company in a structural, long-duration growth theme. This specialization supports differentiated deal flow and expertise across cultivated meat, precision fermentation and enabling tech, increasing the chance of high-return exits over time.
Read all positive factors

Agronomics (ANIC) vs. iShares MSCI United Kingdom ETF (EWC)

Agronomics Business Overview & Revenue Model

Company Description
Agronomics Limited functions as a dedicated investment firm, primarily allocating capital across various financial instruments, including funds, equities, and equity-linked products. Its portfolio spans both publicly traded and privately held comp...
How the Company Makes Money
Agronomics does not primarily generate operating revenue from selling products or services; instead, it seeks returns as an investment company through changes in the value of its portfolio and through liquidity events. Its main economic drivers ar...

Agronomics Financial Statement Overview

Summary
Fundamentals are weak despite a low-risk capital structure. Income statement performance deteriorated sharply into large losses in 2024–2025, and cash flow is persistently negative (operating cash flow and free cash flow negative across all periods), implying the business has not been self-funding. The key offset is a debt-free balance sheet with a still-meaningful equity base, though equity has declined since 2023.
Income Statement
28
Negative
Balance Sheet
70
Positive
Cash Flow
22
Negative
BreakdownTTMJun 2025Jun 2024Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue-11.92M-11.92M-8.34M29.70M440.32K10.67M
Gross Profit-11.92M-11.92M-8.34M29.70M440.32K10.67M
EBITDA-10.05M-26.47M0.0024.57M1.50M2.46M
Net Income-16.18M-32.75M-10.99M22.37M8.36M1.02M
Balance Sheet
Total Assets140.21M124.67M157.44M170.20M146.40M101.65M
Cash, Cash Equivalents and Short-Term Investments2.15M124.62M12.24M169.87M146.30M101.21M
Total Debt0.000.000.000.000.000.00
Total Liabilities234.67K147.60K166.17K1.95M2.49M1.62M
Stockholders Equity139.97M124.52M157.27M168.26M143.91M100.03M
Cash Flow
Free Cash Flow-1.24M-1.12M-15.86M-23.67M-42.21M-12.17M
Operating Cash Flow-1.24M-1.12M-15.86M-23.67M-42.21M-12.17M
Investing Cash Flow2.28M1.59M892.00K10.02M-20.02M-11.21M
Financing Cash Flow0.001.71K1.68K1.01M31.25M71.82M

Agronomics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price6.40
Price Trends
50DMA
6.30
Negative
100DMA
6.46
Negative
200DMA
6.55
Negative
Market Momentum
MACD
-0.31
Positive
RSI
22.67
Positive
STOCH
22.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:ANIC, the sentiment is Negative. The current price of 6.4 is above the 20-day moving average (MA) of 5.80, above the 50-day MA of 6.30, and below the 200-day MA of 6.55, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 22.67 is Positive, neither overbought nor oversold. The STOCH value of 22.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:ANIC.

Agronomics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (68)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
$18.00B11.429.92%3.81%9.73%1.22%
65
Neutral
£953.58M8.758.51%11.00%
64
Neutral
£116.87M8.9811.90%17.93%-22.86%-56.06%
61
Neutral
£560.98M8.697.16%-35.12%
52
Neutral
£111.90M-13.051.79%3.29%-2.25%-353.75%
44
Neutral
£55.25M-3.18-12.24%5.88%
42
Neutral
£14.96M-705.66-16.69%16.98%99.21%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:ANIC
Agronomics
5.10
-3.92
-43.46%
GB:GROW
Molten Ventures
604.00
253.60
72.37%
GB:IPX
Impax Asset Management
95.00
-94.22
-49.79%
GB:IPO
IP Group plc
64.90
9.10
16.31%
GB:MERC
Mercia Asset Management
26.50
-5.50
-17.19%
GB:EMVC
NetScientific
53.00
5.00
10.42%

Agronomics Corporate Events

Business Operations and StrategyM&A Transactions
Tropic Biosciences buys Rahan Meristem to build integrated banana genetics leader
Positive
Jun 25, 2026
Agronomics’ portfolio company Tropic Biosciences has acquired banana propagation specialist Rahan Meristem for $20 million, gaining a network of facilities across Latin America, Asia and the Middle East capable of producing more than 30 mill...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Agronomics Portfolio Firm Bond Pet Foods Wins FDA Nod for Novel Fermented Pet Protein
Positive
Jun 4, 2026
Agronomics said portfolio company Bond Pet Foods has received a US FDA Center for Veterinary Medicine Letter of No Objection for its Lamb Protein Yeast ingredient for use in adult dog food. Developed with Hill’s Pet Nutrition, the precision-...
Business Operations and Strategy
Agronomics Portfolio Firm HydGene Joins Greentown Go Make 2026 Decarbonisation Cohort
Positive
Jun 4, 2026
Agronomics has highlighted that portfolio company HydGene Renewables, a climate-tech firm developing modular biological systems to produce low-carbon hydrogen and industrial chemicals from waste biomass, has been chosen for Greentown Go Make 2026....
Business Operations and StrategyPrivate Placements and Financing
Agronomics boosts SuperMeat stake with premium-funded Series A-4 investment
Positive
May 12, 2026
Agronomics has led a US$6 million initial closing of SuperMeat’s targeted US$10 million Series A-4 round, contributing US$5 million via the issue of 26,805,903 new shares at a significant premium to its recent market price, while an affiliat...
Business Operations and StrategyPrivate Placements and Financing
Agronomics’ Meatly Raises £10.4m to Build Europe’s Largest Cultivated Pet Food Plant
Positive
May 7, 2026
Agronomics’ portfolio company Good Dog Food, trading as Meatly, has closed a £10.4 million Series A round led by climate and consumer-focused investors, lifting its total funding to £17.5 million. Meatly, which develops cultivated ...
Business Operations and StrategyPrivate Placements and Financing
Agronomics-backed Clean Food Group secures funding to scale world’s largest yeast-oil plant
Positive
Apr 15, 2026
Portfolio company Clean Food Group has raised £4.5 million in new funding led by Clean Growth Fund and New Agrarian, alongside a £0.7 million Innovate UK grant, to complete the scale-up of its one million-litre fermentation facility in K...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Agronomics Portfolio Firm Wins Key Approvals for Non-Browning Bananas in Japan and Brazil
Positive
Apr 14, 2026
Agronomics’ portfolio company Tropic Biosciences has secured regulatory approval in Japan and Brazil for its world-first non-browning banana, clearing the way for imports and sales in both markets and local cultivation in Brazil. The move st...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 04, 2026